Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdose Gene Expression Study in Multiple Myeloma
NCT02109861Phase 1Unknown
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of melphalan, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms). Primary endpoint: Change from baseline in gene expression. Status: unknown.
02
Drugs
melphalanbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02109861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109861.